Clopidogrel Versus Aspirin Monotherapy Beyond 1 Year After PCI: The Final 5-Year Results of the STOPDAPT-2 ACS and STOPDAPT-2 Total Cohort - PubMed
5 hours ago
- #Percutaneous Coronary Intervention
- #Cardiovascular Outcomes
- #Antiplatelet Therapy
- Clopidogrel may have ischemic benefits over aspirin as long-term monotherapy post-PCI.
- Two trials, STOPDAPT-2 and STOPDAPT-2 ACS, compared 1-month DAPT followed by clopidogrel vs. 12-month DAPT followed by aspirin.
- Primary endpoint: composite of cardiovascular events (death, MI, stroke, stent thrombosis) and bleeding (TIMI major/minor).
- Clopidogrel showed superiority over aspirin in cardiovascular outcomes in the STOPDAPT-2 ACS cohort (HR 0.70, P=0.03).
- In the pooled STOPDAPT-2 total cohort, clopidogrel significantly reduced cardiovascular events (HR 0.74, P=0.004).
- No increased bleeding risk was observed with clopidogrel monotherapy compared to aspirin.